Literature DB >> 31548809

The role of metronomic chemotherapy in the era of cancer immunotherapy: an oncologist's perspective.

S Y Tsao1.   

Abstract

Entities:  

Year:  2019        PMID： 31548809      PMCID： PMC6726267          DOI： 10.3747/co.26.4853

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


× No keyword cloud information.
  12 in total

Review 1.  Immunogenic cell death in cancer and infectious disease.

Authors:  Lorenzo Galluzzi; Aitziber Buqué; Oliver Kepp; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2016-10-17       Impact factor: 53.106

2.  Efficacy and safety of vinorelbine-capecitabine oral metronomic combination in elderly metastatic breast cancer patients: VICTOR-1 study.

Authors:  Marina E Cazzaniga; Valter Torri; Francesca Riva; Luca Porcu; Federica Cicchiello; Serena Capici; Diego Cortinovis; Nunzio Digiacomo; Paolo Bidoli
Journal:  Tumori       Date:  2017-01-21       Impact factor: 2.098

Review 3.  EGFR TKI combination with immunotherapy in non-small cell lung cancer.

Authors:  Myung-Ju Ahn; Jong-Mu Sun; Se-Hoon Lee; Jin Seok Ahn; Keunchil Park
Journal:  Expert Opin Drug Saf       Date:  2017-03-08       Impact factor: 4.250

Review 4.  Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma.

Authors:  Michael B Atkins; Nizar M Tannir
Journal:  Cancer Treat Rev       Date:  2018-07-20       Impact factor: 12.111

Review 5.  Regulatory T cells: a potential target in cancer immunotherapy.

Authors:  Kohei Shitara; Hiroyoshi Nishikawa
Journal:  Ann N Y Acad Sci       Date:  2018-03-22       Impact factor: 5.691

Review 6.  Regulatory T cells in cancer immunotherapy.

Authors:  Atsushi Tanaka; Shimon Sakaguchi
Journal:  Cell Res       Date:  2016-12-20       Impact factor: 25.617

7.  Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer.

Authors:  Masataka Yoshimoto; Shintaro Takao; Masaru Hirata; Yasushi Okamoto; Sumio Yamashita; Yoshihiro Kawaguchi; Makoto Takami; Hidemi Furusawa; Satoshi Morita; Chigusa Abe; Junichi Sakamoto
Journal:  Cancer Chemother Pharmacol       Date:  2012-04-11       Impact factor: 3.333

8.  Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer.

Authors:  Shivaani Kummar; James L Wade; Amit M Oza; Daniel Sullivan; Alice P Chen; David R Gandara; Jiuping Ji; Robert J Kinders; Lihua Wang; Deborah Allen; Geraldine O'Sullivan Coyne; Seth M Steinberg; James H Doroshow
Journal:  Invest New Drugs       Date:  2016-03-21       Impact factor: 3.850

Review 9.  Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy.

Authors:  Junjie Wu; David J Waxman
Journal:  Cancer Lett       Date:  2018-04-10       Impact factor: 8.679

Review 10.  A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells.

Authors:  Irina Kareva
Journal:  Int J Mol Sci       Date:  2017-10-13       Impact factor: 5.923
View more
  3 in total

1.  Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer.

Authors:  Kabir A Khan; José L Ponce de Léon; Madeleine Benguigui; Ping Xu; Annabelle Chow; William Cruz-Muñoz; Shan Man; Yuval Shaked; Robert S Kerbel
Journal:  NPJ Breast Cancer       Date:  2020-07-20

2.  Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer.

Authors:  Kabir A Khan; José L Ponce de Léon; Madeleine Benguigui; Ping Xu; Annabelle Chow; William Cruz-Muñoz; Shan Man; Yuval Shaked; Robert S Kerbel
Journal:  NPJ Breast Cancer       Date:  2020-07-20

Review 3.  Potential of mRNA vaccines to become versatile cancer vaccines.

Authors:  Shiu-Ying Tsao
Journal:  World J Clin Oncol       Date:  2022-08-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.